Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196, 02196) announced that a drug registration application for Tetracaine Hydrochloride Gel, filed by its subsidiary Shanghai Zhaohui Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. The product is intended for percutaneous local anesthesia prior to venepuncture or venous cannulation and covers adults as well as infants aged over one month.

According to publicly disclosed figures, cumulative research and development investment in this project reached approximately RMB7.19 million as of December 2025. Industry data from IQVIA show that sales of similar Tetracaine Hydrochloride Gel formulations in China reached about RMB443 million in 2024, reflecting potential market demand for topical anesthetic products.

The acceptance of the application does not immediately guarantee commercial production, as further steps—including passing GMP compliance inspections—are required before final approval. The actual market impact of the product will depend on factors such as medical demand, competition, and distribution channels.